The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neogenomics Inc shares valued at $38,000 were purchased by Kelly Michael Aaron on May 27 ’25. At $7.60 per share, Kelly Michael Aaron acquired 5,000 shares. The insider’s holdings grew to 5,000 shares worth approximately $39150.0 following the completion of this transaction.
Also, Stone Warren purchased 5,700 shares, netting a total of over 48,895 in proceeds. Following the buying of shares at $8.58 each, the insider now holds 108,280 shares.
Before that, TETRAULT LYNN A. had added 7,000 shares to its account. In a trade valued at $56,974, the Director bought Neogenomics Inc shares for $8.14 each. Upon closing the transaction, the insider’s holdings increased to 7,000 shares, worth approximately $54810.0.
As published in their initiating research note from Guggenheim on May 15, 2025, Neogenomics Inc [NEO] has been a Neutral. Analysts at Leerink Partners downgraded the stock from ‘”an Outperform”‘ to ‘”a Market perform”‘ outlook in a report released in late April. As of January 13, 2025, The Benchmark Company has decreased its “Buy” rating to a “Hold” for NEO. Earlier on December 10, 2024, Jefferies initiated its rating. Their recommendation was “a Buy” for NEO stock.
Analyzing NEO Stock Performance
During the last five days, there has been a surge of approximately 6.10%. Over the course of the year, Neogenomics Inc shares have dropped approximately -52.49%. Shares of the company reached a 52-week high of $19.11 on 01/08/25 and a 52-week low of $6.08 on 04/30/25.
Support And Resistance Levels for Neogenomics Inc (NEO)
According to the 24-hour chart, there is a support level at 7.60, which, if violated, would cause prices to drop to 7.36. In the upper region, resistance lies at 8.07. The next price resistance is at 8.30. RSI (Relative Strength Index) is 50.59 on the 14-day chart, showing neutral technical sentiment.
